Current opinion in urology · 2026
Engaging in urologic advocacy.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pavuluri Haritha, Plana-Masiques Elena, Collen Sarah, Talwar Ruchika
Аннотация
PURPOSE OF REVIEW: Health policy and political decision-making increasingly shape reimbursement, technology access, workforce capacity, and research funding in urology. Despite these growing influences, many urologists receive little formal training in advocacy. This review is timely given ongoing reimbursement reform, regulatory shifts, cancer policy initiatives, and cross-border health legislation in both the United States and the European Union (EU).
RECENT FINDINGS: Recent literature highlights declining procedural reimbursement, workforce shortages, and regulatory barriers to innovation in the United States, alongside expanding EU-level influence in public health, data governance, research funding, and cancer screening policy. Case studies, including reform of vaginal estrogen labeling, Veterans' prostate cancer legislation, and EU prostate cancer screening recommendations, demonstrate how coordinated clinician advocacy can directly shape policy outcomes. Professional societies and policy offices increasingly serve as structured channels for specialty engagement.
SUMMARY: Advocacy is emerging as a core professional competency for urologists. Structured engagement at institutional, national, and supranational levels enables clinicians to align policy with clinical realities, promote equitable access, and safeguard innovation. Integrating policy literacy into urologic training may strengthen the specialty's ability to influence sustainable, evidence-based health systems.
RECENT FINDINGS: Recent literature highlights declining procedural reimbursement, workforce shortages, and regulatory barriers to innovation in the United States, alongside expanding EU-level influence in public health, data governance, research funding, and cancer screening policy. Case studies, including reform of vaginal estrogen labeling, Veterans' prostate cancer legislation, and EU prostate cancer screening recommendations, demonstrate how coordinated clinician advocacy can directly shape policy outcomes. Professional societies and policy offices increasingly serve as structured channels for specialty engagement.
SUMMARY: Advocacy is emerging as a core professional competency for urologists. Structured engagement at institutional, national, and supranational levels enables clinicians to align policy with clinical realities, promote equitable access, and safeguard innovation. Integrating policy literacy into urologic training may strengthen the specialty's ability to influence sustainable, evidence-based health systems.